Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors

Vythilingum B. ; Cartwright C. ; Hollander E. (2000)

Conference Paper

Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: